The vaccine stimulates the body to produce
antibodies against the virus.
疫苗刺激身体产生针对病毒的抗体。
Antibodies are produced by B cells as part of the immune response.
抗体由B细胞作为免疫反应的一部分产生。
The presence of
antibodies in the blood indicates a previous infection or vaccination.
血液中抗体的存在表明之前有过感染或接种过疫苗。
Monoclonal
antibodies are laboratory-made versions of immune system proteins.
单克隆抗体是实验室制造的免疫系统蛋白质版本。
This test detects specific
antibodies to identify if a person has had COVID-19.
该测试检测特定抗体，以确定一个人是否曾感染过COVID-19。
Antibody-dependent cell-mediated cytotoxicity (ADCC) is an important mechanism for eliminating virus-infected cells.
抗体依赖性细胞介导的细胞毒性(ADCC)是消除病毒感染细胞的重要机制。
The antibody neutralizes the toxin by binding to it, preventing it from harming healthy cells.
抗体通过与毒素结合来中和毒素，防止其伤害健康细胞。
Researchers are developing new therapies that use
antibodies to target cancer cells specifically.
研究人员正在开发使用抗体特异性靶向癌细胞的新疗法。
A positive antibody test for a certain disease suggests exposure but doesn't necessarily mean active infection.
某种疾病的抗体测试呈阳性表明有暴露史，但不一定意味着活动性感染。
The serum contains
antibodies that can be used to treat individuals with compromised immune systems.
血清中含有可用于治疗免疫系统受损个体的抗体。
In March, Shanghai Junshi Biosciences Co Ltd announced collaboration with Singapore-based Rxilient Biotech on development and commercialization of an antibody drug through a joint venture in nine Southeast Asian nations — Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines and Vietnam.
今年3月，上海君实生物科技有限公司宣布，通过在泰国、文莱、柬埔寨、印度尼西亚、老挝、马来西亚、缅甸、菲律宾和越南等九个东南亚国家的合资企业，与新加坡的Rxilent Biotech合作开发抗体药物并将其商业化。
"The company said it is planning to launch the antibody drug in more markets.
该公司表示，计划在更多市场推出这种抗体药物。
Toripalimab is also the only anti-PD-1 monoclonal antibody included in the list for the treatment of melanoma.
托里帕利单抗也是唯一一种被列入黑色素瘤治疗名单的抗PD-1单克隆抗体。
Another set of systems can effectively support production not only in traditional areas such as antibodies, vaccines, recombinant proteins and blood products but also for emerging therapeutics like plasmids, viral vectors and nucleic acids.
另一套系统不仅可以有效支持抗体、疫苗、重组蛋白和血液制品等传统领域的生产，还可以有效支持质粒、病毒载体和核酸等新兴疗法的生产。
Loqtorzi is the first US FDA-approved agent for NPC patients, and is a next-generation, programmed death receptor-1 monoclonal antibody, commonly known as PD-1 antibody.
Loqtorzi是美国食品药品监督管理局批准的第一种用于NPC患者的药物，是下一代程序性死亡受体-1单克隆抗体，通常被称为PD-1抗体。
"The approval of the homegrown antibody is the first of its kind for treating NPC in the US, and that's a milestone for China's innovative medicine industry," said Xu Ruihua, president of Sun Yat-sen University Cancer Center, and the principal investigator of the drug.
“国产抗体的批准是美国首例用于治疗NPC的抗体，这对中国创新医药行业来说是一个里程碑，”该药物的首席研究员、中山大学癌症中心院长徐瑞华说。
For example, we developed COVID antibodies through that model," Basil said.
例如，我们通过该模型开发了新冠病毒抗体，”Basil说。
In March of this year, Sino Biopharmaceutical successfully acquired F-star, which is an internationally leading biotechnology company in the research and development of dual antibody platforms.
今年3月，Sino Biopharmaceutical成功收购了F-star，这是一家在双抗体平台研发方面处于国际领先地位的生物技术公司。
The company has also established strategic partnerships with various China-based biotech and tech companies such as Innovent Biologic, Insilico Medicine, Adagene and Baidu, to accelerate its pace in fields including oncology, AI drug discovery and antibody development technology.
该公司还与Innovent Biologic、Insilico Medicine、Adagene和百度等多家中国生物技术公司建立了战略合作伙伴关系，以加快其在肿瘤学、人工智能药物发现和抗体开发技术等领域的步伐。
Zhu Jingjin, vice-president of China National Biotec Group－Sinopharm's biotech subsidiary－said three virus antibody drugs for COVID-19 have all entered clinical trials with steady progress.
中国国药集团生物技术子公司中国生物技术集团副总裁朱晶晶表示，三种治疗新冠肺炎的病毒抗体药物均已进入临床试验，并取得稳步进展。
Zhu Jingjin, deputy president of China National Biotec Group, China National Pharmaceutical Group's biotech subsidiary, said at a media conference in Beijing on Monday the company's three virus neutralizing antibody drugs for treating COVID-19 have all entered clinical trials and are showing steady progress.
中国医药集团旗下生物技术子公司中国生物技术集团副总裁朱晶晶周一在北京举行的媒体会议上表示，该公司用于治疗新冠肺炎的三种病毒中和抗体药物均已进入临床试验，并显示出稳步进展。
AstraZeneca announced Thursday during the 2022 Taihu Bay Future Healthcare Conference that it has formed a strategic partnership with WuXi Biologics on the local production of Evusheld, a long-acting antibody combination used for the pre-exposure prophylaxis of COVID-19.
阿斯利康周四在2022太湖湾未来医疗保健大会上宣布，它已与无锡生物制品公司就Evusheld的本地生产建立战略合作伙伴关系，Evusheld是一种用于新冠肺炎暴露前预防的长效抗体组合。
AstraZeneca's long-acting antibody combination was authorized for emergency use for pre-exposure prophylaxis of COVID-19 in the US in December 2021.
2021年12月，阿斯利康的长效抗体组合被授权在美国紧急用于新冠肺炎暴露前预防。
We are delighted to work with AstraZeneca to produce the long-acting antibody combination in China and help provide a stable supply of this product.
我们很高兴能与阿斯利康合作，在中国生产长效抗体组合，并帮助提供该产品的稳定供应。
This growth will be mainly fueled by the increasing demand for single-use products in advanced biopharmaceutical manufacturing such as monoclonal antibodies, vaccines and new therapies, he explained.
他解释说，这一增长将主要由先进生物制药制造中对单克隆抗体、疫苗和新疗法等一次性产品的需求增加推动。
The agreement said Adagene, founded in Suzhou, Jiangsu province in 2012, will be responsible for early-stage research activities to develop versions of Sanofi candidate antibodies, using Adagene's proprietary technology.
协议称，2012年在江苏省苏州市成立的阿达吉恩将负责利用阿达吉恩的专有技术开发赛诺菲候选抗体的早期研究活动。
"We look forward to working with Adagene to design antibodies that can help us bring transformative new medicines to people living with cancer," said Valeria Fantin, global head of oncology research at Sanofi.
赛诺菲肿瘤研究全球负责人Valeria Fantin表示：“我们期待着与Adagene合作，设计抗体，帮助我们为癌症患者带来变革性的新药。”。
"Adagene's antibody platform is expected to help us precisely target established, but poorly addressed oncology mechanisms with best-in-class medicines," she said.
她说：“Adagene的抗体平台有望帮助我们用一流的药物准确靶向已建立但解决不力的肿瘤机制。”。
Luo said the proprietary technology is a precision antibody masking platform designed to enable the antibody to bind to its target specifically only after conditional activation of the antibody in target tissues.
罗说，这项专有技术是一种精确的抗体掩蔽平台，旨在使抗体只有在靶组织中有条件激活抗体后才能特异性地与靶结合。
By engineering and developing therapeutic antibody candidates to selectively activate in the tumor microenvironment, the platform is designed to improve safety and tolerability of antibody therapeutics while maintaining clinical activity.
通过设计和开发治疗性候选抗体以在肿瘤微环境中选择性激活，该平台旨在提高抗体治疗的安全性和耐受性，同时保持临床活性。
We've already begun the process to align our global systems, processes, and capabilities to offer world-class solutions to customers working on all bioproduction platforms, including monoclonal antibodies, cell and gene therapies, and mRNA, and supports both therapy and vaccine manufacturing including COVID-19 in China," Wang added.
王补充道：“我们已经开始调整我们的全球系统、流程和能力，为在所有生物生产平台上工作的客户提供世界级的解决方案，包括单克隆抗体、细胞和基因疗法以及mRNA，并支持治疗和疫苗生产，包括中国的新冠肺炎。”。
Zai Lab, a Shanghai-based biopharmaceutical company, and its partner Argenx SE, a Europe-based immunology company, jointly announced that the United States Food and Drug Administration has approved Vyvgart for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive.
上海生物制药公司Zai Lab及其合作伙伴欧洲免疫学公司Argenx SE联合宣布，美国食品和药物管理局已批准Vyvgart用于治疗抗乙酰胆碱受体抗体阳性的成人全身性重症肌无力。
Under the agreement, Boehringer Ingelheim Biopharma, a division of the German pharmaceutical company, will provide process optimization and clinical material manufacturing for the latter's bispecific antibody drug for potential treatment of COVID-19.
根据协议，德国制药公司旗下的勃林格殷格翰生物制药公司将为后者的双特异性抗体药物提供工艺优化和临床材料制造，用于潜在的新冠肺炎治疗。
The drug SYZJ001 is expected to be among the world's first-class innovative, therapeutic bispecific antibodies against COVID-19 that are anticipated to enter clinical stages.
SYZJ001有望成为世界一流的抗新冠肺炎创新治疗双特异性抗体之一，有望进入临床阶段。
Bispecific antibodies can simultaneously bind two separate and unique antigens, which are protein molecules that can provoke an immune response and that are present on the surface of invading or cancerous cells.
双特异性抗体可以同时结合两种单独且独特的抗原，这两种抗原是可以引发免疫反应的蛋白质分子，存在于入侵或癌细胞的表面。
Global life sciences company Cytiva and local biotech company Shengsen signed a strategic cooperation memorandum during the expo, vowing to promote the joint pilot production of antibodies during the research and development phase.
全球生命科学公司Cytiva和当地生物技术公司盛森在博览会期间签署了战略合作备忘录，誓言在研发阶段推动抗体的联合中试生产。
GlaxoSmithKline is showcasing Mepolizumab, the world's first interleukin-5 monoclonal antibody, which has received approval in several countries, including the United States, for treatment on patients with inflammatory diseases caused by the presence of an abnormally increased number of eosinophils in the blood.
葛兰素史克公司正在展示世界上第一种白细胞介素-5单克隆抗体Mepolizumab，该抗体已在包括美国在内的几个国家获得批准，用于治疗因血液中嗜酸性粒细胞数量异常增加而引起的炎症性疾病患者。
The company's more than 10 innovative molecules in discovery, with focus on innate immunity and tumor microenvironment, competed with an innovative antibody drug treating tumors.
该公司超过10种专注于先天免疫和肿瘤微环境的创新分子处于发现阶段，与一种治疗肿瘤的创新抗体药物展开了竞争。
Yet if a person gets a third additional shot six months after he or she finishes the two-shot inoculation program, his or her antibody levels will increase five to 10 times, Chen said.
陈说，但如果一个人在完成两针疫苗接种六个月后打第三针加强针,他的抗体水平会增加五到十倍。
The milestone payment was triggered by the inoculations of the first two patients in the Phase-1/2 clinical trial of its SHP2 inhibitor JAB-3312 in combination with PD-1 antibody pembrolizumab and MEK inhibitor binimetinib, respectively.
该里程碑付款的触发原因是其SHP2抑制剂JAB-3312与PD-1抗体派姆单抗(pembrolizumab)及MEK抑制剂比米替尼(binimetinib)联用，在1/2期临床试验中对首批两位患者进行了接种。具体来说，当该公司在1/2期临床试验中对前两位患者使用其SHP2抑制剂JAB-3312与PD-1抗体派姆单抗和MEK抑制剂比米替尼进行联合治疗时，就触发了里程碑付款条款。这表明试验已进展到特定阶段，满足了预设的支付条件。
Chinese biotech company BeiGene Ltd announced on Thursday the approval from the China National Medical Products Administration to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab, at its biologics facility in Guangzhou, Guangdong province.
中国生物科技公司 BeiGene Ltd 周四宣布，已获得中国国家药品监督管理局的批准，在广东省广州市的生物制品工厂开始生产其获批的抗PD-1抗体药物替雷利珠单抗的商业化供应。
In December 2020, the Company and Utrecht University jointly announced a deal to out-license the global rights of development and commercialization for a fully human antibody ABBV-47D11 (HBM9022) to United States-based biopharmaceutical company AbbVie and authorized it to initiate clinical trials.
在2020年12月，该公司与乌得勒支大学联合宣布，已与美国生物制药公司艾伯维达成协议，将全人源抗体ABBV-47D11（HBM9022）在全球范围内的开发和商业化权利独家授权给艾伯维，并授权其启动临床试验。
In December 2020, Clover reported positive clinical data from its Phase 1 trial, demonstrating its protein-based COVID-19 S-Trimer vaccine candidate in combination with Dynavax's CpG 1018 induces strong immune response, including neutralizing antibodies and cell-mediated immunity, as well as favorable safety and tolerability profiles in the adult and elderly participants.
在2020年12月，Clover报告了其Phase 1试验的积极临床数据，显示其基于蛋白质的COVID-19 S-Trimer疫苗候选产品与Dynavax的CpG 1018结合，能够诱导强烈的免疫反应，包括中和抗体和细胞介导的免疫反应，以及在成人和老年参与者中具有良好的安全性和耐受性特征。
At the beginning of last year, BeiGene worked with United Kingdom-based biopharmaceutical company EUSA Pharma to introduce a monoclonal antibody drug for neuroblastoma for Chinese patients.
去年年初， BeiGene与英国生物制药公司EUSA Pharma合作，为中国患者引进了一种针对神经母细胞瘤的单克隆抗体药物。
With the introduction of the monoclonal antibody drug, neuroblastoma patients are able to get medical treatment, bringing a chance of survival and cure for them.
随着单克隆抗体药物的引入，神经母细胞瘤患者现在能够接受医疗治疗，从而为他们带来了生存和治愈的希望。
In 2018, the NMPA included BeiGene's monoclonal antibody drug for neuroblastoma into the first batch of drugs on its badly as an imported drug for the clinical use catalog.
2018年，NMPA将 BeiGene 的一种针对神经母细胞瘤的单克隆抗体药物纳入首批临床急需境外新药名单，允许进口使用。
Its second drug at commercial stage, the anti-PD-1 antibody tislelizumab, also proved to be a success targeting at both domestic and global markets.
其第二个进入商业阶段的药物，抗PD-1抗体替雷利珠单抗，也在中国和全球市场取得了成功。
The fourth plant will mainly research, develop and produce anti-tumor monoclonal antibody and related cancer drugs independently, said Wang Xiaodong，founder of BeiGene and a foreign associate of Chinese Academy of Science, at the commencement ceremony.
“这座第四工厂将主要进行抗肿瘤单克隆抗体及相应抗癌药物的自主研发与生产，” BeiGene 创始人、中国科学院外籍院士王小东在奠基仪式上表示。
Biotech company BeiGene Ltd announced Thursday its anti-PD-1 antibody tislelizumab has received approval from the country's National Medical Products Administration for use in combination with two chemotherapy regimens as a first-line treatment for patients with advanced squamous non-small cell lung cancer.
生物科技公司 BeiGene Ltd 周四宣布，其抗 PD-1 抗体替雷利珠单抗已获得中国国家药品监督管理局的批准，可用于与两种化疗方案联合使用，作为晚期鳞状非小细胞肺癌患者的一线治疗。
xa0xa0In China,xa0the phase I/II trials were conducted with results showing the vaccine candidate can induce neutralizing antibodies among over 90 percent of volunteers who received two doses of vaccination in both adults and the elderly.
在中国，该疫苗的I/II期临床试验已经完成，结果显示，在接种两剂疫苗的志愿者中，超过90%的成人和老年人能够产生中和抗体。
At the booth of Eli Lilly, the US company and its Chinese partners from academia, hospitals and industry discussed the latest development of their joint efforts regarding clinical trials of two COVID-19-related antibody treatments and a marketed JAK inhibitor to treat complications of COVID-19.
在美国礼来公司的展台上，该公司与中国来自学术界、医院和工业界的合作伙伴讨论了他们关于两种与COVID-19相关的抗体治疗临床试验的最新进展，以及一种用于治疗COVID-19并发症的上市JAK抑制剂。
Zhang Jing, an expert of clinical pharmacology from Shanghai Huashan Hospital, said that one of the antibodies, the first of its kind to undergo clinical trials among healthy individuals in the world, has entered the second phase of clinical trials in China and some neighboring countries.
上海华山医院临床药理学专家张静表示，其中一款抗体药物在全球范围内首个对健康人体开展临床试验，目前已在中国及部分邻国进入二期临床试验阶段。
Promising preclinical and preliminary Phase 1 data – which will be published in a peer-reviewed publication in the near future - indicate that S-Trimer is well-tolerated and produces strong neutralizing antibody and Th1-biased cell-mediated immune responses, which merit ongoing evaluation of the vaccine candidate, Clover said in a press release.
Clover公司在一个新闻发布会上表示，即将在一份同行评审的出版物上发表的有希望的临床前和初步1期数据显示，S-Trimer耐受性良好，并能产生强效的中和抗体和Th1偏向的细胞介导免疫反应，这使得该疫苗候选物值得继续评估。
Recent instances include Amgen signing a global collaboration for oncology drug development with BeiGene, and Lilly licensing a neutralizing antibody asset for COVID-19 from Junshi Biosciences.
Lemzoparlimab, also known as TJC4, is an anti-CD47 monoclonal antibody discovered by the Shanghai-based company to treat multiple forms of cancer.
But the development of therapeutic CD47 antibodies has been hampered by hematologic side-effects, such as severe anemia, because of the binding of CD47 on red blood cells.
Lemzoparlimab is designed to minimize inherent binding to normal red blood cells while preserving its strong anti-tumor activity, a critical attribute in potentially differentiating lemzoparlimab from other antibodies of the same class currently in development, the company said.
Zhang Yang, founder and CEO of ZXBio Co Ltd, has bold visions for his antibody production business in China.
"With an initial investment of 13 million yuan, ZXBio has developed more than 50 flow cytometry antibody diagnostic products, which unique surface substances－antigens－to assist physicians more precisely diagnose patients with complicated diseases, such as autoimmune disease, cancer, and coronavirus infection.
It allows the customization of antibody manufacturing based on market needs.
As a new entrant of the antibody diagnostic industry, Zhang plans to further tap the growing demand for diverse antibody diagnostic reagents with a novel manufacturing facility.
All of the subjects have proved to have produced a high-concentration of antibodies," the company said.
Although the vaccine is inactivated, the antigenic compound it contains can stimulate production of antibodies in humans.
The world's first inactivated vaccine has shown a 100 percent antibody positive conversion rate, with all subjects producing antibodies according to the latest clinical results from its producer.
The company said a total of 1,120 volunteers were vaccinated during the phase-1 and phase-2 clinical trials, all of whom produced high-titer antibodies.
In the 18-to-59-year-old age group, those who got two doses of vaccine based on the 0-and-28-day procedure demonstrated 100 percent antibody positive conversion rate, while those who got two doses based on the 0-and-14-day procedure and 0-and-21-day procedure showed a 97.6 percent antibody positive conversion rate.
Upon arrival in China, they will need to take another COVID-19 and antibody test, and have to undergo a mandatory quarantine for 48 hours in Shanghai.
Chinese medical device company Guangzhou Wondfo Biotech Co Ltd said in an official statement on Tuesday that its SARS-CoV-2 antibody testing kits exported overseas met the quality requirements of China's National Medical Products Administration and countries that they were exported to, and vowed to proactively provide product training to medical staff in each country to ensure the proper use of the test.
The statement came after British media outlets reported that Wondfo's SARS-CoV-2 antibody testing kits exported to the United Kingdom were unqualified and didn't work out very well, and that the testing kits might need a month of trial period before being used.
As stated in the product description, the company's antibody test is for rapid, qualitative detection of the SARS-CoV-2 IgG/IgM antibody in a human whole blood, serum or plasma sample.
Later on, when the human body begins to produce specific antibodies through the immune response, the sensitivity and detection rate of an antibody testing kit could rise to a high level, he said.
"Therefore, for infected cases who have gone through the window period, using antibody testing as a supplementary testing method effectively raises the detection rate," Li added.
Wondfo said that between March 9 and Sunday, it had delivered millions of SARS-CoV-2 antibody testing kits to more than 70 countries and regions worldwide.
Thanks to much-improved research and development capabilities, Chinese companies were able to develop nucleic acid test kits quickly in January, soon after Chinese scientists published the genomic sequence of the virus, and then developed antibody tests later in February.
The National Medical Products Administration said it had approved 11 nucleic acid test kits and eight antibody test kits as of March 17.
And Jiangsu Medomics Medical Technology Co Ltd gave away 10,000 antibody test kits.
"Guangzhou Wondfo Biotech Co Ltd, a POCT (point-of-care testing) leader in China, announced on March 6 that its three newly developed SARS-CoV-2 antibody tests had received CE marking.
The Wondfo SARS-CoV-2 Antibody Test based on lateral flow method, approved by the NMPA on Feb 22 as the country's first POCT test for the SARS-CoV-2, can detect both IgM and IgG antibodies in human serum, plasma and whole blood samples within 15 minutes, effectively accelerating the on-site screening for suspected patients.
The other two antibody test products, Finecare SARS-CoV-2 Antibody Test and Finecare SARS-CoV-2 IgM Test, which use fluorescence immunochromatographic assay, are yet to be approved by the NMPA, but are even faster-they can detect either IgM antibody or both IgM and IgG antibodies within 10 minutes.
It has also established a protocol to prepare the convalescent plasma treatment, which includes rigorous virus inactivation measures and several procedures to neutralize antibodies and pathogenic microorganisms.
In addition, two antibody detection kits jointly developed by Wuhan Institute of Virology and a pharmaceutical company have started production and will soon be put into the market.
Wu noted that the new funds will allow the company to advance its clinical pipeline of novel bispecific antibodies.
The 2nd Merck Emerging Biotech China GrantThe grant recipients are:∙ Hangzhou ImmunoMAB Inc, for developing cell therapy, antibody-drug conjugates and bispecific monoclonal antibodies.
∙ Beijing Beyond Biotechnology, for developing long-acting fusion proteins, bispecific and multispecific antibodies for the treatment of cancer, diabetes and autoimmune disease.
∙ Hangzhou JUST Biotherapeutics Co Ltd, for developing antibody and antibody-like biotherapeutics for the treatment of infectious disease.
∙ Chengdu ConMed Biosciences Inc, for developing new therapeutic antibody drugs using Hybridoma screening and cell line development platform.
Among the eight antibody drugs approved and available in the market last year, five were developed by companies based in Zhangjiang.
The 8 billion yuan investment industrial base will focus on antibodies, vaccines, cell therapy and gene therapy.
In May, Spevigo, a monoclonal antibody medication for treating rare skin diseases, filed for a new indication — the prevention of generalized pustular psoriasis.
At the exhibition hall, North China Pharmaceutical Group displayed Ormutivimab Injection, the first domestically produced rabies monoclonal antibody in China.
On April 12, Jiangsu province-based Chiatai Tianqing Pharmaceutical Group signed an agreement with Singaporean company Specialised Therapeutics, offering the latter the exclusive right to commercialize a new anti-PD1 antibody in Australia, New Zealand, Papua New Guinea and across Southeast Asia.
In March, Shanghai-based Junshi Biosciences granted commercialization rights of its monoclonal antibody in Southeast Asia to Excellmab, a joint venture of Rxilient Biotech.
China National Pharmaceutical Group Co Ltd, or Sinopharm, announced recently it had developed four Omicron-specific vaccine candidates, including inactivated, recombinant protein, and mRNA varieties, as well as an inhalable monoclonal antibody for COVID-19 prevention.
Currently, it is accelerating the introduction of innovative drugs to China and enhancing accessibility, which include a first-in-class antibody conjugate drug.
Small molecule drugs, new types of vaccines and new-generation antibody drugs will be the major sectors that Shanghai's biopharmaceutical companies will focus on in the near future, according to attendees of the IBIWS.
Wang Jingsong, founder, chairman and CEO of HBM, said the drug candidate is one of the company's representative innovative bispecific antibodies generated from its self-developed antibody development platform called HBICE and has significant potential value on a global basis.
A bispecific antibody is a molecule designed to recognize two different antigens or two different epitopes on the same antigen to treat tumors and other diseases and therefore is widely believed to have superior clinical therapeutic effects compared with traditional monoclonal antibodies.
According to Wang with HBM, the company is capable of designing unique and novel formats of antibodies, including bispecific and multispecific antibodies.
Improved innovation, manufacturing savvy help domestic producers make inroads overseasThanks to much-improved research and development capabilities, Chinese companies able to quickly develop a myriad of nucleic acid, antigen and antibody test kits after the outbreak of COVID-19 have seen a spike in orders for the products in recent months.
A global leader in SHP2 inhibitor development, the company has finished phase-1 clinical study of an SHP2 inhibitor drug candidate and determined recommended doses of monotherapy and combination therapy with PD-1 antibody.
They include a PD-1 antibody for tumor immunotherapy, a tumor-targeting drug and a PARP inhibitor also used for cancer treatment.
其中包括一款用于肿瘤免疫疗法的PD-1抗体、一款靶向肿瘤的药物以及一款同样用于癌症治疗的PARP抑制剂。
I-Mab, a Shanghai-based biomedicine startup that has built an innovative and competitive pipeline mainly in oncology and autoimmune diseases since its founding in 2016, reached a strategic collaboration agreement with AbbVie from the US over I-Mab's CD47 antibody for next-phase R&D and global commercialization.
自2016年成立以来，专注于在肿瘤学和自身免疫性疾病领域构建创新且具有竞争力产品研发管线的上海生物医药初创公司——天境生物，已就其CD47抗体与美国艾伯维达成战略协作协议，涉及该抗体的下一阶段研发及全球商业化。
Independently operated by the BGI Health Ethiopia, the high-end laboratory provides passengers with RT-PCR and IgM antibody tests for COVID-19.
这个高端实验室由BGI Health Ethiopia独立运营，为乘客提供COVID-19的RT-PCR和IgM抗体测试。
All these have been driving the country to move toward an early stage of innovation and engage more actively in original indication expansion, combo therapies and novel antibody work.
所有这些因素都在推动该国向创新的早期阶段发展，并更积极地参与到原创性适应症拓展、联合疗法以及新型抗体工作中。
"As China deepens its understanding in areas such as oncology pathogenesis, biological mechanisms and antibody engineering, we expect this progress to continue.
“随着中国在肿瘤病理学、生物机制和抗体工程等领域理解的不断深入，我们期待这一进展将持续下去。”
Before he returned to his post after vacation, Tanvir had both PCR and antibody tests thrice and was quarantined for 14 days at the power plant.
在返回岗位之前，Tanvir 在休假期间进行了三次 PCR 和抗体检测，并在发电厂隔离了 14 天。
"Therapeutic antibodies and vaccines, cell therapies and gene therapies will be the main areas of the base's focus," said Shanghai Pharma, a Fortune 500 enterprise, in a news release.
治疗性抗体和疫苗、细胞疗法和基因疗法将是该基地关注的主要领域，"《财富》500强企业上海医药在一份新闻稿中表示。
The public service platform for innovative incubation at the base will exceed 50,000 sq m, the production area for antibodies will reach 100,000 sq m and the scale of bioreactors will reach 120,000 liters.
基地内的创新孵化公共服务平台面积将超过5万平方米，抗体生产区域将达到10万平方米，生物反应器规模将达到12万升。
Some of them have been able to conduct world-class R&D of cutting-edge treatments, such as PD-1/PD-L1 inhibitors, anti-CD47 monoclonal antibodies, and other revolutionary cancer therapeutics.
他们中的一些已经能够进行世界级的前沿治疗的研发，比如PD-1/PD-L1抑制剂、抗CD47单克隆抗体，以及其他革命性的癌症治疗方法。
In April, China's National Medical Products Administration approved the company's anti-PD-1 antibody tislelizumab as a treatment for patients with locally advanced or metastatic urothelial carcinoma, the most common type of bladder cancer, following the therapy's initial approval in classic Hodgkin's lymphoma in December 2019.
在4月，中国国家药品监督管理局批准了该公司的抗PD-1抗体tislelizumab用于治疗局部晚期或转移性尿路上皮癌（最常见的膀胱癌）的患者，此前该疗法于2019年12月首次被批准用于经典霍奇金淋巴瘤。